N,N,N'-三甲基-1,4-丁二胺 | 20383-23-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N,N,N'-三甲基-1,4-丁二胺
• 英文名称: N-(4-dimethylaminobutyl)-N-methylamine
• 英文别名: N,N,N'-trimethylbutanediamine；N,N,N-trimethylbutanediamine；N,N,N'-trimethyl-butanediyldiamine；N,N,N'-Trimethyl-butandiyldiamin；N.N.N'-Trimethyl-α.ω-tetramethylendiamin；N,N,N'-Trimethylputrescin；[4-(Dimethylamino)butyl](methyl)amine；N,N',N'-trimethylbutane-1,4-diamine
• CAS: 20383-23-7
• 化学式: C₇H₁₈N₂
• mdl: MFCD12161293
• 分子量: 130.233
• InChiKey: UOTKNWSJLVKOJR-UHFFFAOYSA-N

物化性质

• 沸点：
  165.3±8.0℃ (760 Torr)
• 密度：
  0.813±0.06 g/cm3 (20 ºC 760 Torr)
• 闪点：
  42.4±9.4℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N,N,N'-三甲基-1,4-丁二胺 在 lithium aluminium tetrahydride 作用下， 以 乙醚 、 乙醇 为溶剂， 生成 2,7-Dimethyl-11-amino-2,7-diaza-undecan
  参考文献：
  名称：

  Somin,I.N., Journal of Organic Chemistry USSR (English Translation), 1968, vol. 4, # 4, p. 122 - 125

  摘要：

  DOI：
• 作为产物：
  描述：

  N,N'-二甲基-1,4-丁二胺 在 盐酸 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 N,N,N'-三甲基-1,4-丁二胺
  参考文献：
  名称：

  In vitro cytotoxicity on human ovarian cancer cells by T-type calcium channel blockers

  摘要：

  The growth inhibition of human cancer cells via T-type Ca2+ channel blockade has been well known. Herein, a series of new 3,4-dihydroquinazoline derivatives were synthesized via a brief SAR study on KYS05090 template and evaluated for both T-type Ca2+ channel (Ca(v)3.1) blockade and cytotoxicity on three human ovarian cancer cells (SK-OV-3, A2780 and A2780-T). Most of compounds except 6i generally exhibited more potent cytotoxicity on SK-OV-3 than mibefradil as a positive control regardless of the degree of T-type channel blockade. In particular, eight compounds (KYS05090, 6a and 6c-6h) showing strong channel blockade exhibited almost equal and more potent cytotoxicity on A2780 when compared to mibefradil. On A2780-T paclitaxel-resistant human ovarian carcinoma, two compounds (KYS05090 and 6d) were 20-fold more active than mibefradil. With respect to cell cycle arrest effect on A2780 and A2780-T cells, KYS05090 induced large proportion of sub-G(1) phase in the cell cycle progression of A2780 and A2780-T, meaning the induction of cancer cell death instead of cell cycle arrest via blocking T-type Ca2+ channel. Among new analogues, compounds 6g and 6h induced cell cycle arrest at G(1) phase of A2780 and A2780-T cells in dose-dependent manner and exhibited strong anti-proliferation effects of ovarian cancer cells by blocking T-type Ca2+ channel. Furthermore, 6g and 6h possessing strong cytotoxic effects could induce apoptosis of A2780 cells, which was detected by confocal micrographs using DAPI staining. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.10.049

文献信息

• BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20160333009A1

  公开（公告）日：2016-11-17

  The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDOL) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R 1 , R 2a , R 2b , R n , R m , and R t are as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.

  本公开提供了式I的吲哌酮2,3-二氧化酶1（IDOL）抑制剂： 或其药学上可接受的盐，其中X、L、n、m、R 1 、R 2a 、R 2b 、R n 、R m 和R t 如本文所定义，以及包括式I化合物的药物组合物，或其药学上可接受的盐，并使用这些方法来治疗由IDO1介导的疾病。
• Pyrrolopyridinylpyrimidin-2-ylamine derivatives
  申请人：Wucherer-Plietker Margarita

  公开号：US20110218198A1

  公开（公告）日：2011-09-08

  Compounds of the formula I in which X, R 1 , R 2 , R 3 , R 4 and R 6 have the meanings indicated in Claim 1 , are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.

  公式I中X、R1、R2、R3、R4和R6具有权利要求书中指示的含义，是细胞增殖/细胞活力的抑制剂，可用于肿瘤的治疗。
• [EN] TETRA-AZA-HETEROCYCLES AS PHOSPHATIDYLINOSITOL-3-KINASES (PI3-KINASES) INHIBITOR<br/>[FR] TÉTRA-AZA-HÉTÉROCYCLES COMME INHIBITEUR DE PHOSPHATIDYLINOSITOL-3-KINASES (PI3-KINASES)
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010043676A1

  公开（公告）日：2010-04-22

  The present invention encompasses compounds of general formula (1) wherein R1 to R4, A, X, m and k are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

  本发明涵盖了一般式（1）中R1至R4、A、X、m和k的定义如权利要求书中所述的化合物，适用于治疗以细胞过度或异常增殖为特征的疾病，并用于制备具有上述特性的药物。
• 2,4-diamino-pyrimidines as aurora inhibitors
  申请人：Zahn Karl Stephan

  公开号：US20070032514A1

  公开（公告）日：2007-02-08

  The present invention encompasses compounds of general formula (1) wherein R 1 to R 3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.

  本发明涵盖了一般式（1）的化合物 其中 R 1 至 R 3 如权利要求书中所定义，适用于治疗以细胞过度或异常增殖为特征的疾病，并用于制备具有上述特性的药物组合物。
• New compounds
  申请人：Zahn Stephan Karl

  公开号：US20090163467A1

  公开（公告）日：2009-06-25

  The present invention encompasses compounds of general formula (1) wherein R 1 , R 2 , R 4 , X, m, n and p are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition having the above-mentioned properties.

  本发明涵盖了一般式（1）的化合物 其中 R 1 ，R 2 ，R 4 ，X，m，n和p的定义如权利要求书中所述 ，适用于治疗以细胞过度或异常增殖为特征的疾病，并且用于制备具有上述特性的药物组合物。